Cardiovascular Care Clinical Trials

Cardiovascular (Heart) Clinical Trials

Cardiovascular Care Clinical Trials

If you or someone you love is living with a cardiovascular condition, clinical trials may provide a promising alternative option. The Bluhm Cardiovascular Institute at Northwestern Medicine offers access to clinical trials that look for new ways to diagnose, treat and/or prevent heart and vascular disease.

For more information regarding cardiovascular clinical trials, please visit:

  • Bluhm Cardiovascular Institute at Northwestern Memorial Hospital, send an email or call 312.926.4000​.
  • Bluhm Cardiovascular Institute at Central DuPage Hospital, call the Northwestern Medicine Office of Research at 630.933.6528. TTY for the hearing impaired 630.933.4833.

Current Clinical Trials

Condition being studied: persistent or longstanding persistent atrial fibrillation

aMAZE Study: Left Atrial Appendage Ligation with the LARIATTM Suture Delivery System as Adjunctive Therapy to Pulmonary Vein Isolation for Persistent or Longstanding Persistent Atrial Fibrillation
General Inclusion Criteria:

  • Age ≥ 18 years and ≤ 80 years
  • Diagnosis of symptomatic continuous persistent or longstanding persistent non-valvular atrial fibrillation
  • Failed at least one Class I or III anti-arrhythmic drug
Summary: This study is being conducted to determine whether the LARIAT procedure can help treat patients with persistent or longstanding persistent atrial fibrillation when performed in addition to catheter ablation. The LARIAT procedure closes off the left atrial appendage non-surgically using a suture loop. Patients will be randomized to either receive the LARIAT procedure followed by catheter ablation or catheter ablation alone.
Study website: www.amazetrial.com
Site Principal Investigator: Dr. Todd Tomson
Contact Information: Stefanie.Miller@nm.org



Condition being studied: Critical Limb Ischemia

BEST-CLI Trial: Randomized, Multicenter, Controlled Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia
General Inclusion Criteria:

  • Age ≥ 18 years
  • Peripheral arterial occlusive disease of the arteries below the inguinal ligament
  • Critical Limb Ischemia, defined as arterial insufficiency with gangrene, non-healing ischemic ulcer, or rest pain
Summary: This study is comparing two treatments for critical limb ischemia to determine which treatment is best for patient outcomes. Patients will be randomized to receive either endovascular therapy or bypass surgery as treatment for their critical limb ischemia.
Study website: http://www.bestcli.com/
Site Principal Investigator: Dr. Julia Wilkenson
Contact Information: Stefanie.Miller@nm.org



Condition being studied: Post-Thrombotic Syndrome

The C-TRACT Trial: Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy
General Inclusion Criteria:

  • Age ≥ 18 years
  • Post-thrombotic syndrome (PTS) of at least moderate severity
  • Suspicion for, or documentation of, iliac vein obstruction (complete or partial)
Summary: This study is being conducted to determine whether endovascular therapy reduces the severity of PTS and improves patient quality of life after vein damage caused by deep vein thrombosis. Patients will be randomized to either receive endovascular therapy in addition to optimal PTS care or optimal PTS care alone. Optimal PTS care includes lifestyle measures, medical therapy, compression, and venous ulcer care.
Study website: https://bloodclotstudy.wustl.edu
Site Principal Investigator: Dr. Joseph Schneider
Contact Information: Stefanie.Miller@nm.org



Condition being studied: Acute Decompensated Heart Failure (inpatient population)

PARAGLIDE-HF: A multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8-week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safety and tolerability of inhospital initiation of LCZ696 compared to valsartan in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization
General Inclusion Criteria:

  • Age ≥ 40 years
  • Hospitalized with acute decompensated heart failure with preserved ejection fraction (HFpEF)
  • HFpEF with most recent left ventricular ejection fraction > 40%
  • Elevated NT-proBNP or BNP during hospitalization
Summary: This study is being conducted to assess the effect of in-hospital initiation of sacubitril/valsartan on patient outcomes, including the proportional change in NT-proBNP from baseline, re-hospitalizations, and adverse events such as symptomatic hypotension, hyperkalemia, and angioedema.
Study website: https://clinicaltrials.gov/ct2/show/NCT03988634
Site Principal Investigator: Dr. Michelle Montpetit
Contact Information: Stefanie.Miller@nm.org